OBJECTIVE: To study the relationship of maximum cancer core length (MCCL), on targeted biopsy (TB) of magnetic resonance imaging (MRI)-visible index lesions, to volume of that tumour found at radical prostatectomy (RP). PATIENTS AND METHODS: In all, 205 men undergoing fusion biopsy and RP were divided into two groups: 136 in whom the MCCL came from an index MRI-visible lesion (TB) and 69 in whom MCCL came from a non-targeted lesion (non-targeted biopsy [NTB]). MRI was 3-T multi-parametric and biopsy was via MRI-ultrasonography fusion. RESULTS: In the TB group, MCCL correlated with volume of clinically significant index tumours (ρ = 0.44-0.60, P < 0.01). The correlation was similar for first and repeat biopsy and for transition and peripheral zone lesions (ρ = 0.42-0.49, P < 0.01). No correlations were found in the NTB group. TB MCCL (6-10 and >10 mm) and MRI lesion diameter (>20 mm) were independently associated with tumour volume. TB MCCLs >10 mm and Gleason scores >7 were each associated with pathological T3 disease (odds ratios 5.73 and 5.04, respectively), but MRI lesion diameter lesion was not. CONCLUSIONS: MCCL on a TB from an MRI-visible lesion is an independent predictor of both cancer volume and pathological stage. This relationship does not exist for MCCL from a NTB core. Quantifying CCL on MRI-TBs may have a value, not previously described, to risk-stratify patients with prostate cancer before treatment.
OBJECTIVE: To study the relationship of maximum cancer core length (MCCL), on targeted biopsy (TB) of magnetic resonance imaging (MRI)-visible index lesions, to volume of that tumour found at radical prostatectomy (RP). PATIENTS AND METHODS: In all, 205 men undergoing fusion biopsy and RP were divided into two groups: 136 in whom the MCCL came from an index MRI-visible lesion (TB) and 69 in whom MCCL came from a non-targeted lesion (non-targeted biopsy [NTB]). MRI was 3-T multi-parametric and biopsy was via MRI-ultrasonography fusion. RESULTS: In the TB group, MCCL correlated with volume of clinically significant index tumours (ρ = 0.44-0.60, P < 0.01). The correlation was similar for first and repeat biopsy and for transition and peripheral zone lesions (ρ = 0.42-0.49, P < 0.01). No correlations were found in the NTB group. TB MCCL (6-10 and >10 mm) and MRI lesion diameter (>20 mm) were independently associated with tumour volume. TB MCCLs >10 mm and Gleason scores >7 were each associated with pathological T3 disease (odds ratios 5.73 and 5.04, respectively), but MRI lesion diameter lesion was not. CONCLUSIONS: MCCL on a TB from an MRI-visible lesion is an independent predictor of both cancer volume and pathological stage. This relationship does not exist for MCCL from a NTB core. Quantifying CCL on MRI-TBs may have a value, not previously described, to risk-stratify patients with prostate cancer before treatment.
Authors: Maisa M Q Quintal; Luciana R Meirelles; Leandro L L Freitas; Luis A Magna; Ubirajara Ferreira; Athanase Billis Journal: Int Urol Nephrol Date: 2011-02-22 Impact factor: 2.370
Authors: Liang Cheng; Christopher K Poulos; Chong-Xian Pan; Timothy D Jones; Joanne K Daggy; John N Eble; Michael O Koch Journal: J Urol Date: 2005-09 Impact factor: 7.450
Authors: Theo H van der Kwast; Mahul B Amin; Athanase Billis; Jonathan I Epstein; David Griffiths; Peter A Humphrey; Rodolfo Montironi; Thomas M Wheeler; John R Srigley; Lars Egevad; Brett Delahunt Journal: Mod Pathol Date: 2010-09-03 Impact factor: 7.842
Authors: Lori E Eichelberger; Michael O Koch; Joanne K Daggy; Thomas M Ulbright; John N Eble; Liang Cheng Journal: Am J Clin Pathol Date: 2003-09 Impact factor: 2.493
Authors: Hashim Uddin Ahmed; Yipeng Hu; Tim Carter; Nimalan Arumainayagam; Emilie Lecornet; Alex Freeman; David Hawkes; Dean C Barratt; Mark Emberton Journal: J Urol Date: 2011-06-15 Impact factor: 7.450
Authors: Masatomo Kaneko; Dordaneh Sugano; Amir H Lebastchi; Vinay Duddalwar; Jamal Nabhani; Christopher Haiman; Inderbir S Gill; Giovanni E Cacciamani; Andre Luis Abreu Journal: Curr Urol Rep Date: 2021-03-22 Impact factor: 3.092
Authors: Kira Kornienko; Fabian Siegel; Angelika Borkowetz; Manuela A Hoffmann; Martin Drerup; Verena Lieb; Johannes Bruendl; Thomas Höfner; Hannes Cash; Jost von Hardenberg; Niklas Westhoff Journal: Prostate Cancer Prostatic Dis Date: 2021-12-17 Impact factor: 5.455
Authors: Iulia Andras; Emanuel Darius Cata; Andreea Serban; Pierre Kadula; Teodora Telecan; Maximilian Buzoianu; Maria Bungardean; Dan Vasile Stanca; Ioan Coman; Nicolae Crisan Journal: Medicina (Kaunas) Date: 2021-05-22 Impact factor: 2.430
Authors: Lina Maria Carmona Echeverria; Aiman Haider; Alex Freeman; Urszula Stopka-Farooqui; Avi Rosenfeld; Benjamin S Simpson; Yipeng Hu; David Hawkes; Hayley Pye; Susan Heavey; Vasilis Stavrinides; Joseph M Norris; Ahmed El-Shater Bosaily; Cristina Cardona Barrena; Simon Bott; Louise Brown; Nick Burns-Cox; Tim Dudderidge; Alastair Henderson; Richard Hindley; Richard Kaplan; Alex Kirkham; Robert Oldroyd; Maneesh Ghei; Raj Persad; Shonit Punwani; Derek Rosario; Iqbal Shergill; Mathias Winkler; Hashim U Ahmed; Mark Emberton; Hayley C Whitaker Journal: Sci Rep Date: 2020-10-14 Impact factor: 4.379